Navigation Links
eResearchTechnology Reports First Quarter 2008 Results
Date:5/5/2008

Q1 2008 Net Revenues - $33.7 million vs. $21.1 million in Q1 2007 - an

increase of 59.7%; a record for eRT Q1 2008 Diluted Net Income per Share - $0.11 vs $0.04 in Q1 2007 - an

increase of 175.0%

Q1 2008 New Bookings increase to $50.1 million; a record for eRT

Increasing 2008 Guidance

PHILADELPHIA, May 5/PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), (Nasdaq: ERES), a leading provider of centralized ECG and eClinical technology, ePRO and other services to the pharmaceutical, biotechnology, medical device and related industries, announced today results for the quarter ended March 31, 2008.

Highlights for the first quarter of 2008 were:

-- Record quarterly net revenues of $33.7 million, including $3.3 million

of net revenues from Covance Cardiac Safety Services, Inc. (CCSS), a

59.7% increase from the first quarter of 2007;

-- Diluted net income per share of $0.11, up 175.0% from the first quarter

of 2007;

-- Gross margin of $17.7 million for a gross margin percentage of 52.5% up

4.9 percentage points from the first quarter of 2007. The gross margin

percentage was negatively impacted by CCSS, which generated net

revenues of $3.3 million while incurring expenses of $3.2 million;

-- Income before income taxes margin percentage of 26.5%, up 9.2

percentage points from the first quarter of 2007. The income before

income taxes margin percentage was negatively impacted by CCSS and the

integration of CCSS into eRT, which combined generated a loss before

income taxes of $1.4 million;

-- Record bookings of $50
'/>"/>

SOURCE eResearchTechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. eResearchTechnology to Present at the Deutsche Bank 33rd Annual Healthcare Conference on May 7th 2008
2. eResearchTechnology, Inc. to Announce 2008 First Quarter Results on May 5, 2008
3. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
4. eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results
5. eResearchTechnology, Inc. to Announce 2007 Fourth Quarter Results on February 26, 2008
6. eResearchTechnology to Present at the UBS Global Healthcare Services Conference 2008 on February 11th
7. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
8. MannKind Corporation Reports First Quarter Financial Results
9. Verenium Reports Financial Results for the First Quarter 2008
10. ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance
11. United Therapeutics Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):MSU researcher unveils new approach to treat lower back pain 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 3National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 4Superior offspring without genetic modification 2Johns Hopkins leads first 16 patient multicenter domino donor kidney transplant 51007 1Johns Hopkins leads first 16 patient multicenter domino donor kidney transplant 51007 2Johns Hopkins leads first 16 patient multicenter domino donor kidney transplant 51007 3DaVitas Award Winning Training Program for New Teammates Reaches Milestone With 100th DaVita Academy in Baltimore Maryland 51006 1DaVitas Award Winning Training Program for New Teammates Reaches Milestone With 100th DaVita Academy in Baltimore Maryland 51006 2Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 1Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 2Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 3Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 4Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 5Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 6Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 7Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 8